Lymphatic Anomaly Diagnosis Using Targeted SNV-Guided Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods and treatments for lymphatic disorders such as lymphangiomatosis and generalized lymphatic anomalies (GLAs) are lacking, particularly in identifying genetic markers and providing targeted therapeutic interventions.
Innovation Solution
Identification of specific single nucleotide variants (SNVs) in genes like EPHB4, PIK3R4, PIK3R6, mTOR, and ARAF through exome sequencing, followed by targeted administration of mTOR, PI3K, and MEK/ERK inhibitors to treat lymphatic anomalies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for lymphatic disorders, then general assessment is possible, but diagnostic accuracy is insufficient to identify specific genetic markers
Solution Approach 1:
The patent segments the complex diagnostic process by identifying and testing for specific single nucleotide variants (SNVs) in particular genes (EPHB4, PIK3R4, PIK3R6, mTOR, ARAF) rather than performing comprehensive genomic analysis. This targeted approach to specific genetic markers improves diagnostic precision while reducing overall testing complexity.
Solution Approach 2:
The patent changes the diagnostic parameter from general lymphatic disorder assessment to specific genetic variant detection. By focusing on identifying particular SNVs in defined genes, the diagnostic method transitions from phenotypic evaluation to genotypic characterization, thereby improving accuracy.
2Reliability
If targeted therapeutic interventions are implemented, then treatment efficacy improves, but treatment complexity increases due to multiple inhibitor classes
Solution Approach 1:
The patent applies local quality by selecting specific inhibitor classes (mTOR, PI3K, MEK/ERK) that target the particular genetic mutations identified in the patient. Rather than using broad-spectrum therapies, the treatment is locally optimized to match the specific molecular defect, improving efficacy while managing complexity through precision.
Solution Approach 2:
The patent implements feedback by using genetic test results to guide therapeutic selection. The diagnostic information about specific SNVs feeds into the treatment decision-making process, creating a closed-loop system where diagnosis directly informs targeted therapy selection.
3Measurement precision
If comprehensive genetic screening is performed, then identification of all potential markers is possible, but cost and time requirements increase significantly
Solution Approach 1:
The patent applies preliminary action by pre-identifying the specific genes and SNVs most commonly associated with lymphatic disorders. This beforehand selection of target markers allows for focused testing that achieves comprehensive identification of clinically relevant mutations without the time cost of screening the entire genome.
Solution Approach 2:
The patent extracts only the most clinically relevant genetic markers (specific SNVs in five key genes) from the vast genome for testing. This extraction approach identifies all actionable genetic information while avoiding the time consumption of analyzing non-critical genomic regions.
Data Source
AI summary
Compositions and methods for the diagnosis and treatment of lymphatic anomaly are disclosed.